Role of microglia in disease

Microglia are the primary immune cells of the Central Nervous System, similar to peripheral macrophages. They respond to pathogens and injury by changing morphology and migrating to the site of infection/injury, where they destroy pathogens and remove damaged cells.

As part of their response they secrete cytokines, chemokines, prostaglandins, and reactive oxygen species, which help to direct the immune response. Additionally, they are instrumental in the resolution of the inflammatory response, through the production of anti-inflammatory cytokines. Microglia have also been extensively studied for their harmful roles in neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Multiple sclerosis, as well as cardiac diseases, glaucoma, and viral and bacterial infections.

Role in chronic neuroinflammation

The word neuroinflammation has come to stand for chronic, central nervous system (CNS) specific, inflammation-like glial responses that may produce neurodegenerative symptoms such as plaque formation, dystrophic neurite growth, and excessive tau phosphorylation.[1] It is important to distinguish between acute and chronic neuroinflammation. Acute neuroinflammation is generally caused by some neuronal injury after which microglia migrate to the injured site engulfing dead cells and debris.[1] The term neuroinflammation generally refers to more chronic, sustained injury when the responses of microglial cells contribute to and expand the neurodestructive effects, worsening the disease process.[1]

When microglia are activated they take on an amoeboid shape and they alter their gene expression. Altered gene expression leads to the production of numerous potentially neurotoxic mediators. These mediators are important in the normal functions of microglia and their production is usually decreased once their task is complete.[2] In chronic neuroinflammation, microglia remain activated for an extended period during which the production of mediators is sustained longer than usual.[2] This increase in mediators contributes to neuronal death.[2]

Neuroinflammation is distinct from inflammation in other organs, but does include some similar mechanisms such as the localized production of chemoattractant molecules to the site of inflammation.[2] The following list contains a few of the numerous substances that are secreted when microglia are activated:

Cytokines

Microglia activate the proinflammatory cytokines IFN-γ, IL-1α, IL-1β and TNF-α in the CNS.[3][2] Direct injection of the cytokines IL-1α, IL-1β and TNF-α into the CNS result in local inflammatory responses and neuronal degradation. Cytokines play a potential role in neurodegeneration when microglia remain in a sustained activated state.[2] This is in contrast with the potential neurotrophic (inducing growth of neurons) actions of these cytokines during acute neuroinflammation.[2]

Chemokines

Chemokines are cytokines that stimulate directional migration of inflammatory cells in vitro and in vivo.[2] Chemokines are divided into four main subfamilies: C, CC, CXC, and CX3C. Microglial cells are sources of some chemokines and express the monocyte chemoattractant protein-1 (MCP-1) chemokine in particular.[2] Other inflammatory cytokines like IL-1β and TNF-α, as well as bacterial-derived lipopolysaccharide (LPS) may stimulate microglia to produce MCP-1, MIP-1α, and MIP-1β.[2] Microglia can express CCR3, CCR5, CXCL8, CXCR4, and CX3CR1 in vitro.[3][2] Chemokines are proinflammatory and therefore contribute to the neuroinflammation process.[2]

Proteases

When microglia are activated they induce the synthesis and secretion of proteolytic enzymes that are potentially involved in many functions.[2] There are a number of proteases that possess the potential to degrade both the extracellular matrix and neuronal cells that are in the neighborhood of the microglia releasing these compounds.[2] These proteases include; cathepsins B, L, and S, the matrix metalloproteinases MMP-1, MMP-2, MMP-3, and MMP-9, and the metalloprotease-disintegrin ADAM8 (plasminogen) which forms outside microglia and degrades the extracellular matrix.[2] Both Cathepsin B, MMP-1 and MMP-3 have been found to be increased in Alzheimer's disease (AD) and cathepsin B is increased in multiple sclerosis (MS).[2] Elastase, another protease, could have large negative effects on the extracellular matrix.[2]

Amyloid precursor protein

Microglia synthesize amyloid precursor protein (APP) in response to excitotoxic injury.[2] Plaques result from abnormal proteolytic cleavage of membrane bound APP.[2] Amyloid plaques can stimulate microglia to produce neurotoxic compounds such as cytokines, excitotoxin, nitric oxide and lipophylic amines, which all cause neural damage.[4] Plaques in Alzheimer's disease contain activated microglia.[2] A study has shown that direct injection of amyloid into brain tissue activates microglia, which reduces the number of neurons.[4] Microglia have also been suggested as a possible source of secreted β amyloid.[2]

Role in neurodegeneration

Microglia also have a role in neurodegenerative disorders, which are characterized by progressive cell loss in specific neuronal populations.[2] "Many of the normal trophic functions of glia may be lost or overwhelmed when the cells become chronically activated in progressive neurodegenerative disorders, for there is abundant evidence that in such disorders, activated glia play destructive roles by direct and indirect inflammatory attack."[2] The following are prominent examples of microglial cells' role in neurodegenerative disorders.

Alzheimer's disease

Alzheimer's disease (AD) is a progressive, neurodegenerative disease where the brain develops abnormal clumps (amyloid plaques) and tangled fiber bundles (neurofibrillary tangles).[5]

Genetics

Many genes associated with Alzheimer's Disease risk are highly expressed in microglia. In late-onset (non-familial) Alzheimer's Disease, a common variant of SPI1 expression is implicated in Alzheimer's risk. It encodes PU.1, a transcription factor necessary for microglial development. TREM2, a cell surface receptor on microglia, is associated with Alzheimer's as well, notably interacting with Apolipoprotein E (another Alzheimer's Disease risk factor). [6]

Microglia Activity

There are many activated microglia over-expressing IL-1 in the brains of Alzheimer patients that are distributed with both Aβ plaques and neurofibrillary tangles.[7] This over expression of IL-1 leads to excessive tau phosphorylation that is related to tangle development in Alzheimer's disease.[7]

Many activated microglia are found to be associated with amyloid deposits in the brains of Alzheimer's patients.[2] Microglia interact with β-amyloid plaques through cell surface receptors that are linked to tyrosine kinase based signaling cascades that induce inflammation.[2] When microglia interact with the deposited fibrillar forms of β-amyloid it leads to the conversion of the microglia into an activated cell and results in the synthesis and secretion of cytokines and other proteins that are neurotoxic.[2]

One preliminary model as to how this would occur involves a positive feedback loop. When activated, microglia will secrete proteases, cytokines, and reactive oxygen species. The cytokines may induce neighboring cells to synthesize amyloid precursor protein. The proteases then possibly could cause the cleaving required to turn precursor molecules into the beta amyloid that characterizes the disease. Then, the oxygen species encourage the aggregation of beta amyloid in order to form plaques. The growing size of these plaques then in turn triggers the action of even more microglia, which then secrete more cytokines, proteases, and oxygen species, thus amplifying the neurodegeneration.[8]

Treatment

Non-steroidal anti-inflammatory drugs (NSAIDs) have proven to be effective in reducing the risk of AD.[2] "Sustained treatment with NSAIDs lowers the risk of AD by 55%, delays disease onset, attenuates symptomatic severity and slows the loss of cognitive abilities. The main cellular target for NSAIDs is thought to be microglia. This is supported by the fact that in patients taking NSAIDs the number of activated microglia is decreased by 65%."[2]

Parkinson's disease

Parkinson's disease is a movement disorder in which the dopamine-producing neurons in the brain do not function as they should; the neurons of the substantia nigra become dysfunctional and eventually die, leaving a lack of dopamine input into the striatum. Glial cell line-derived neurotrophic factor (GDNF) may have the ability to chemoprotect the cells of the substantia nigra. A small study is (2017) in the recruitment stage for participants who will undergo AAV2-GDNF gene transfer via surgical infusion into their brains, in the hope of ameliorating Parkinson's symptoms.[9]

Multiple sclerosis

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) characterized by focal lesions of inflammation, axonal loss, gliosis, and demyelination that affect the white and gray matter. In MS patients, destruction of myelin in the CNS is associated with activated macrophages or microglia, which are thought to be involved in the disease pathogenesis.[10]

While most of the findings of microglial activation are non-MS specific, the M1 activation (CD40, CD86) is specific for this disease.[11]

Cardiovascular Diseases

Recently microglial activation has been reported in rats with myocardial infarction (Rana et al.,2010). This activation was specific to brain nuclei involved in cardiovascular regulation suggesting possible role of microglial activation in progression to heart failure.

Role in glaucoma

Several studies have proved the changes occurring in the microglia of the inner plexiform and of the outer plexiform layers of the retina.[12][13][14] Also a new software to automatize the count of microglial cells in the retina has been published.[15] However, depletion of microglia from the retina and optic nerve does not affect the degeneration process of retinal ganglion cells after acute injury of the optic nerve.[16] Thus, it remains to be studied whether microglia play a functional role in the degeneration process in glaucoma.

Role in glioma

Gliomas are complex brain tumors composed of heterogeneous populations of neoplastic as well as non-neoplastic cells.[17][18] Not only tumor cells, but also non-tumor cells of the microenvironment contribute to cancer progression and response to treatment.[19] Tumor-associated macrophages/microglia (TAMs) are the main infiltrate in gliomas, comprising up to 40% of the tumor mass.[20] TAMs are either of peripheral origin (macrophages) or representing brain-intrinsic, yolk sac-derived microglia, that create a supportive stroma for neoplastic cell expansion and invasion.[19] Crosstalk between tumor cells and TAMs is characterized by the release of growth factors and cytokines by TAMs in response to factors produced by cancer cells.[21] In this manner, TAMs facilitate tumor proliferation, survival and migration. Microglial TAMs are mainly found in the tumor margin, while macrophage TAMs are found in the tumor core and in regions of necrosis.[22] Blood-derived TAMs upregulate immunosuppressive cytokines and show an altered metabolism compared to microglial TAMs. Therefore, high degrees of infiltration with blood-derived TAMs, but not microglial TAMs, correlates with significantly inferior survival in low-grade glioma.[22]

Role in viral infections

Human immunodeficiency virus

The infection of mononuclear phagocytes with HIV-1 is an important element in the development of HIV-associated dementia complex (HAD).[23] The only brain cell type that is "productively" infected with the virus are microglial cells.[23] It has also become clear that neurotoxic mediators released from brain microglia play an important role in the pathogenesis of HIV-1.[23]

"HIV-1 can enter the microglial cell via CD4 receptors and chemokine co-receptors such as CCR3, CCR5, and CXCR4, with CCR5 being the most important of these. Humans with double allelic loss of CCR5 are virtually immune to HIV acquired via the sexual route (though can be infected by IV transmission of CXCR4 tropic viruses). IL-4 and IL-10 enhance the entry and replication of HIV-1 in microglia through the up-regulation of CD4 and CCR5 expression, respectively. The chemokines CCL5/RANTES, CCL3/MIP-1α, CCL4/MIP-1β, all of which bind to CCR5, are inhibitory to HIV-1 replication in microglial cells, apparently by their ability to block viral entry."[23]

Infected microglia contain viral particles intracellularly.[23] There is a correlation between the severity of dementia and microglial production of neurotoxins.[23]

One discrepancy in HAD is the limited number of HIV-1 infected microglia in comparison to the many CNS abnormalities that occur.[23] This suggests that chemical factors that are released from microglial cells are contributing to neuronal loss. "It has become more and more apparent that HIV-1 infected microglial cells actively secrete both endogenous neurotoxins such as TNF-α, IL-1β, CXCL8/IL-8, glutamate, quinolinic acid, platelet activating factor, eicosanoids, and NO as well as the neurotoxic viral proteins Tat, gp120, and gp41."[23]

Microglia are the main target of HIV-1 in the brain. When activated by HIV-1 or viral proteins, they secrete or induce other cells to secrete neurotoxic factors; this process is accompanied by neuronal dysfunction (HAD).[23]

Herpes simplex virus

Herpes simplex virus (HSV) can cause herpes encephalitis in babies and immunocompetent adults. Studies have shown that long-term neuroimmune activation persists after the herpes infection in patients.[23] Microglia produce cytokines that are toxic to neurons; this may be a mechanism underlying HSV-related CNS damage.[23] It has been found that "active microglial cells in HSV encephalitis patients do persist for more than 12 months after antiviral treatment."[23]

Role in bacterial infections

Lipopolysaccharide (LPS) is the major component of the outer membrane of a gram-negative bacterial cell wall. LPS has been shown to activate microglia in vitro and stimulates microglia to produce cytokines, chemokines, and prostaglandins.[23] "Although LPS has been used as a classic activating agent, a recent study of rat microglia demonstrated that prolonged LPS exposure induces a distinctly different activated state from that in microglia acutely exposed to LPS."[23]

Streptococcus pneumoniae

Streptococcus pneumoniae is the most common cause of bacterial meningitis. It is primarily localized to the subarachnoid space while cytokines and chemokines are produced inside the blood–brain barrier.[23] Microglia interact with streptococcus via their TLR2 receptor; this interaction then activates microglia to produce nitric oxide which is neurotoxic.[24] The inflammatory response, triggered by microglia, may cause intracerebral edema.[23]

Role in parasitic infections

Plasmodium falciparum

Plasmodium falciparum is a parasite that causes malaria in humans.[23] A serious complication of malaria is cerebral malaria (CM).[23] CM occurs when red blood cells break through the blood–brain barrier, causing microhemorrhages, ischemia and glial cell growth.[23] This can lead to microglial aggregates called Durck's granulomas.[23] Recent research has indicated that microglia play a major role in the pathogenesis of CM.[23]

Trichobilharzia regenti

Trichobilharzia regenti is a neuropathogenic schistosome which migrates in a central nervous system of birds and mammals.[25] In mice, microglia accumulate in the parasite migratory tracks and around damaged or dying worms.[26] In vitro, microglia produce nitric oxide and proinflammatory cytokines IL-6 and TNF-alpha after exposure to parasite antigens, which suggests their role both in maintaining inflammation and tissue pathology.[27]

Role in neuropathic pain

Microglia have been implicated in neuropathic pain. They become activated in response to nerve injury, as demonstrated by several animal models.[28] Activated microglia release substances that excite pain-sensitive neurons, including prostaglandins and reactive oxygen species, through the purinergic signaling mechanisms.[29][30] Moreover, microglia also release of proinflammatory molecules through the stimulation of purinergic receptors, including IL1-β, IL-6, and TNF-α.[31][32][33] The release of these molecules is mediated by the P2X7 receptor and creates a positive feedback loop, exacerbating the pain response.[34]

A causal role for microglia in the pathogenesis of neuropathic pain has been demonstrated through P2X4 receptor.[35] P2X4 receptors are upregulated following injury and the increase in purinergic signaling activates p38-mitogen-activated protein kinase (p38 MAPK). The increase in p38 MAPK signaling leads to greater microglial release of brain-derived neurotrophic factor (BDNF).[36][37] BDNF released from microglia induces neuronal hyperexcitability through interaction with the TrkB receptor.[38]

Therapeutic development has focused on finding purinergic signaling blockers. There has been some success with P2X7 blockers, A-438079 and A-740003, however there are no selective P2X4 receptor antagonists to date.[39][40][41]

As a target to treat neuroinflammation

Inhibition of activation

The retina is helpful to control neuroinflammation is to inhibit microglial activation. Studies on microglia have shown that they are activated by diverse stimuli but they are dependent on activation of mitogen-activated protein kinase (MAPK).[2] Previous approaches to down-regulate activated microglia focused on immunosuppressants.[2] Recently, minocycline (a tetracycline derivative) has shown down-regulation of microglial MAPK.[2] Another promising treatment is CPI-1189, which induces cell death in a TNF α-inhibiting compound that also down-regulates MAPK.[2] Recent study shows that nicergoline (Sermion) suppresses the production of proinflammatory cytokines and superoxide anion by activated microglia.[42] Microglial activation can be inhibited by MIF (microglia/macrophage inhibitory factor, tuftsin fragment 1–3, Thr-Lys-Pro). MIF-treated mice showed reduced brain injury and improved neurologic function in a mouse model of collagenase-induced intracerebral hemorrhage.[43][44]

Regulation of chemokine receptor

The chemokine receptor, CX3CR1, is expressed by microglia in the central nervous system.[45] Fractalkine (CX3CL1) is the exclusive ligand for CX3CR1 and is made as a transmembrane glycoprotein from which a chemokine can be released.[45] Cardona, et al. stated in 2006 that "using three different in vivo models, we show that CX3CR1 deficiency dysregulates microglial responses, resulting in neurotoxicity."[45] Further studies into how CX3CR1 regulates microglial neurotoxicity could lead to new therapeutic strategies for neuroprotection.[45]

Inhibition of amyloid deposition

Inhibitors of amyloid deposition include the enzymes responsible for the production of extracellular amyloid such as β-secretase and γ-secretase inhibitors.[2] Currently the γ-secretase inhibitors are in phase II clinical trials as a treatment for Alzheimer's disease but they have immunosuppressive properties, which could limit their use.[2] Another strategy involves increasing the antibodies against a fragment of amyloid.[2] This treatment is also in phase II clinical trials for the treatment of Alzheimer's disease.[2]

Inhibition of cytokine synthesis

Glucocorticosteroids (GCS) are anti-inflammatory steroids that inhibit both central and peripheral cytokine synthesis and action.[2] In a study conducted by Kalipada Pahan from the Department of Pediatrics at the Medical University of South Carolina, both lovastatin and sodium phenylacetate were found to inhibit TNF-α, IL-1β, and IL-6 in rat microglia.[46] This shows that the mevalonate pathway plays a role in controlling the expression of cytokines in microglia and may be important in developing drugs to treat neurodegenerative diseases.[46] Naltrexone may provide a solution to the inflammatory mediators produced by microglia. Although naltrexone's main action is to competitively bind to opioid receptors, new research shows that naltrexone, when given in low doses once per day (low-dose naltrexone), can inhibit cytokine synthesis by microglia cells. This mechanism is still being investigated, but there are already studies that indicate that it helps some patients suffering from fibromyalgia syndrome. Naltrexone shows more promise than GCSs because the GCSs inhibit immune system function more generally, increase allergic reactions and, as the name implies, increase blood glucose levels.[47][48]

References
  1. Streit WJ (September 2006). "Microglial senescence: does the brain's immune system have an expiration date?". Trends in Neurosciences. 29 (9): 506–10. doi:10.1016/j.tins.2006.07.001. PMID 16859761.
  2. Wood, Paul (2003). Neuroinflammation: Mechanisms and Management. Humana Press.
  3. Shattuck EC, Muehlenbein MP (May 2015). "Human sickness behavior: Ultimate and proximate explanations". American Journal of Physical Anthropology. 157 (1): 1–18. doi:10.1002/ajpa.22698. PMID 25639499.
  4. Golden N, Darmadipura S (2007). "The Role of Microglia as Prime Component of CNS Immune System in Acute and Chronic Neuroinflammation" (PDF). Folica Medica Indonesiana. 43 (1): 54–8.
  5. "National Institute of Neurological Disorders and Stroke". NINDS Alzheimer's Disease Information Page. November 14, 2007.
  6. Hansen, DV; Hanson, JE; Sheng, M (5 February 2018). "Microglia in Alzheimer's disease". The Journal of Cell Biology. 217 (2): 459–472. doi:10.1083/jcb.201709069. PMC 5800817. PMID 29196460.
  7. Mrak RE, Griffin WS (March 2005). "Glia and their cytokines in progression of neurodegeneration". Neurobiology of Aging. 26 (3): 349–54. doi:10.1016/j.neurobiolaging.2004.05.010. PMID 15639313.
  8. Streit WJ, Kincaid-Colton CA (November 1995). "The brain's immune system". Scientific American. 273 (5): 54–5, 58–61. Bibcode:1995SciAm.273e..54S. doi:10.1038/scientificamerican1195-54. PMID 8966536.
  9. "Parkinson's Disease: Hope Through Research". National Institute of Neurological Disorders and Stroke. November 13, 2007.
  10. Luo C, Jian C, Liao Y, Huang Q, Wu Y, Liu X, Zou D, Wu Y (2017). "The role of microglia in multiple sclerosis". Neuropsychiatric Disease and Treatment. 13: 1661–1667. doi:10.2147/NDT.S140634. PMC 5499932. PMID 28721047.
  11. M.Vercellino et al, Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study. Journal of Neuroimmunology Volume 312, 15 November 2017, Pages 49-58
  12. Rojas B, Gallego BI, Ramírez AI, Salazar JJ, de Hoz R, Valiente-Soriano FJ, et al. (July 2014). "Microglia in mouse retina contralateral to experimental glaucoma exhibit multiple signs of activation in all retinal layers". Journal of Neuroinflammation. 11: 133. doi:10.1186/1742-2094-11-133. PMC 4128533. PMID 25064005.
  13. de Hoz R, Gallego BI, Ramírez AI, Rojas B, Salazar JJ, Valiente-Soriano FJ, Avilés-Trigueros M, Villegas-Perez MP, Vidal-Sanz M, Triviño A, Ramírez JM (2013). "Rod-like microglia are restricted to eyes with laser-induced ocular hypertension but absent from the microglial changes in the contralateral untreated eye". PLOS ONE. 8 (12): e83733. Bibcode:2013PLoSO...883733D. doi:10.1371/journal.pone.0083733. PMC 3867486. PMID 24367610.
  14. Gallego BI, Salazar JJ, de Hoz R, Rojas B, Ramírez AI, Salinas-Navarro M, et al. (May 2012). "IOP induces upregulation of GFAP and MHC-II and microglia reactivity in mice retina contralateral to experimental glaucoma". Journal of Neuroinflammation. 9: 92. doi:10.1186/1742-2094-9-92. PMC 3410794. PMID 22583833.
  15. de Gracia P, Gallego BI, Rojas B, Ramírez AI, de Hoz R, Salazar JJ, Triviño A, Ramírez JM (2015). "Automatic Counting of Microglial Cells in Healthy and Glaucomatous Mouse Retinas". PLOS ONE. 10 (11): e0143278. Bibcode:2015PLoSO..1043278D. doi:10.1371/journal.pone.0143278. PMC 4651327. PMID 26580208.
  16. Hilla AM, Diekmann H, Fischer D (2017). "Microglia Are Irrelevant for Neuronal Degeneration and Axon Regeneration after Acute Injury". The Journal of Neuroscience. 37 (25): 6113–6124. doi:10.1523/JNEUROSCI.0584-17.2017. PMID 28539419.
  17. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. (June 2014). "Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma". Science. 344 (6190): 1396–401. Bibcode:2014Sci...344.1396P. doi:10.1126/science.1254257. PMC 4123637. PMID 24925914.
  18. Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, et al. (March 2017). "Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq". Science. 355 (6332): eaai8478. doi:10.1126/science.aai8478. PMC 5519096. PMID 28360267.
  19. Hambardzumyan D, Gutmann DH, Kettenmann H (January 2016). "The role of microglia and macrophages in glioma maintenance and progression". Nature Neuroscience. 19 (1): 20–7. doi:10.1038/nn.4185. PMC 4876023. PMID 26713745.
  20. Lapa C, Linsenmann T, Lückerath K, Samnick S, Herrmann K, Stoffer C, Ernestus RI, Buck AK, Löhr M, Monoranu CM (2015). "Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?". PLOS ONE. 10 (3): e0122269. Bibcode:2015PLoSO..1022269L. doi:10.1371/journal.pone.0122269. PMC 4373835. PMID 25807228.
  21. Matias D, Predes D, Niemeyer Filho P, Lopes MC, Abreu JG, Lima FR, Moura Neto V (August 2017). "Microglia-glioblastoma interactions: New role for Wnt signaling". Biochimica et Biophysica Acta. 1868 (1): 333–340. doi:10.1016/j.bbcan.2017.05.007. PMID 28554667.
  22. Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, et al. (December 2017). "Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment". Genome Biology. 18 (1): 234. doi:10.1186/s13059-017-1362-4. PMC 5738907. PMID 29262845.
  23. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, Peterson PK (October 2004). "Role of microglia in central nervous system infections". Clinical Microbiology Reviews. 17 (4): 942–64, table of contents. doi:10.1128/CMR.17.4.942-964.2004. PMC 523558. PMID 15489356.
  24. Lehnardt S, Wennekamp J, Freyer D, Liedtke C, Krueger C, Nitsch R, Bechmann I, Weber JR, Henneke P (November 2007). "TLR2 and caspase-8 are essential for group B Streptococcus-induced apoptosis in microglia". Journal of Immunology. 179 (9): 6134–43. doi:10.4049/jimmunol.179.9.6134. PMID 17947688.
  25. Bulantová J, Macháček T, Panská L, Krejčí F, Karch J, Jährling N, Saghafi S, Dodt HU, Horák P (April 2016). "Trichobilharzia regenti (Schistosomatidae): 3D imaging techniques in characterization of larval migration through the CNS of vertebrates". Micron. 83: 62–71. doi:10.1016/j.micron.2016.01.009. PMID 26897588.
  26. Lichtenbergová L, Lassmann H, Jones MK, Kolářová L, Horák P (August 2011). "Trichobilharzia regenti: host immune response in the pathogenesis of neuroinfection in mice". Experimental Parasitology. 128 (4): 328–35. doi:10.1016/j.exppara.2011.04.006. PMID 21554878.
  27. Macháček T, Panská L, Dvořáková H, Horák P (November 2016). "Nitric oxide and cytokine production by glial cells exposed in vitro to neuropathogenic schistosome Trichobilharzia regenti". Parasites & Vectors. 9 (1): 579. doi:10.1186/s13071-016-1869-7. PMC 5109812. PMID 27842570.
  28. Watkins LR, Milligan ED, Maier SF (August 2001). "Glial activation: a driving force for pathological pain". Trends in Neurosciences. 24 (8): 450–5. doi:10.1016/S0166-2236(00)01854-3. PMID 11476884.
  29. Barberà-Cremades M, Baroja-Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrín P (July 2012). "P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release". FASEB Journal. 26 (7): 2951–62. doi:10.1096/fj.12-205765. PMID 22490780.
  30. Bartlett R, Yerbury JJ, Sluyter R (2013). "P2X7 receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia". Mediators of Inflammation. 2013: 1–18. doi:10.1155/2013/271813. PMC 3568910. PMID 23431238.
  31. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB, Malcangio M (January 2010). "P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide". The Journal of Neuroscience. 30 (2): 573–82. doi:10.1523/JNEUROSCI.3295-09.2010. PMC 2880485. PMID 20071520.
  32. Shigemoto-Mogami Y, Koizumi S, Tsuda M, Ohsawa K, Kohsaka S, Inoue K (September 2001). "Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5". Journal of Neurochemistry. 78 (6): 1339–49. doi:10.1046/j.1471-4159.2001.00514.x. PMID 11579142.
  33. Hide I, Tanaka M, Inoue A, Nakajima K, Kohsaka S, Inoue K, Nakata Y (September 2000). "Extracellular ATP triggers tumor necrosis factor-alpha release from rat microglia". Journal of Neurochemistry. 75 (3): 965–72. doi:10.1046/j.1471-4159.2000.0750965.x. PMID 10936177.
  34. Hains BC, Waxman SG (April 2006). "Activated microglia contribute to the maintenance of chronic pain after spinal cord injury". The Journal of Neuroscience. 26 (16): 4308–17. doi:10.1523/JNEUROSCI.0003-06.2006. PMID 16624951.
  35. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K (August 2003). "P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury". Nature. 424 (6950): 778–83. Bibcode:2003Natur.424..778T. doi:10.1038/nature01786. PMID 12917686.
  36. Ulmann L, Hatcher JP, Hughes JP, Chaumont S, Green PJ, Conquet F, et al. (October 2008). "Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain". The Journal of Neuroscience. 28 (44): 11263–8. doi:10.1523/JNEUROSCI.2308-08.2008. PMID 18971468.
  37. Trang T, Beggs S, Wan X, Salter MW (March 2009). "P2X4-receptor-mediated synthesis and release of brain-derived neurotrophic factor in microglia is dependent on calcium and p38-mitogen-activated protein kinase activation". The Journal of Neuroscience. 29 (11): 3518–28. doi:10.1523/JNEUROSCI.5714-08.2009. PMC 3589565. PMID 19295157.
  38. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, Inoue K, et al. (December 2005). "BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain". Nature. 438 (7070): 1017–21. Bibcode:2005Natur.438.1017C. doi:10.1038/nature04223. PMID 16355225.
  39. {{cite journal | vauthors = Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF | display-authors = 6 | title = A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 319 | issue = 3 | pages = 1376–85 | date = December 2006 | pmid = 16982702 | doi = 10.1124/jpet.106.111559 }}
  40. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, et al. (June 2006). "Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists". Journal of Medicinal Chemistry. 49 (12): 3659–66. doi:10.1021/jm051202e. PMID 16759108.
  41. Burnstock G (September 2013). "Purinergic mechanisms and pain--an update". European Journal of Pharmacology. 716 (1–3): 24–40. doi:10.1016/j.ejphar.2013.01.078. PMID 23524093.
  42. Mizuno T, Kuno R, Nitta A, Nabeshima T, Zhang G, Kawanokuchi J, et al. (December 2005). "Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes". Brain Research. 1066 (1–2): 78–85. doi:10.1016/j.brainres.2005.10.050. PMID 16325157.
  43. Wang J, Rogove AD, Tsirka AE, Tsirka SE (November 2003). "Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage". Annals of Neurology. 54 (5): 655–64. doi:10.1002/ana.10750. PMID 14595655.
  44. Wang J, Tsirka SE (March 2005). "Tuftsin fragment 1-3 is beneficial when delivered after the induction of intracerebral hemorrhage". Stroke. 36 (3): 613–8. doi:10.1161/01.STR.0000155729.12931.8f. PMID 15692122.
  45. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (July 2006). "Control of microglial neurotoxicity by the fractalkine receptor". Nature Neuroscience. 9 (7): 917–24. doi:10.1038/nn1715. PMID 16732273.
  46. Pahan K, Sheikh FG, Namboodiri AM, Singh I (December 1997). "Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages". The Journal of Clinical Investigation. 100 (11): 2671–9. doi:10.1172/JCI119812. PMC 508470. PMID 9389730.
  47. Younger J, Mackey S (2009). "Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study". Pain Medicine. 10 (4): 663–72. doi:10.1111/j.1526-4637.2009.00613.x. PMC 2891387. PMID 19453963.
  48. Younger J, Noor N, McCue R, Mackey S (February 2013). "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels". Arthritis and Rheumatism. 65 (2): 529–38. doi:10.1002/art.37734. PMID 23359310.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.